Dr. Ridker's research efforts are primarily supported by RO1 research grants from the National Heart, Lung, and Blood Institute (NHLBI), a Distinguished Clinical Scientist Award from the Doris Duke Charitable Foundation, and through philanthropic research grants from the Leducq Foundation and the Donald W Reynolds Foundation. Dr. Ridker additionally directs an NHLBI-funded institutional National Research Service Award (training grant) in cardiovascular epidemiology at the Brigham and Women's Hospital and Harvard Medical School. Dr. Ridker has been the recipient of both a Clinician Scientist Award (1992-1997) and an Established Investigator Award (1997-2002) from the American Heart Association. A frequent invited lecturer at national and international conferences, Dr. Ridker lists among his honors elected membership into the American Society for Clinical Investigation (ASCI), the American Epidemiological Society (AES), and the American Association of Physicians (AAP). Citing his pioneering work on inflammation, CRP, and atherothrombosis, Time Magazine honored Dr. Ridker as one of America's Ten Best Researchers in Science and Medicine in 2001 and as one of the "Time 100" in 2004. Dr Ridker currently serves on the Board of External Experts for the National Heart Lung and Blood Institute. In addition to his work in cardiovascular epidemiology, Dr Ridker has been the Principal Investigator or Study Chairman of several multinational clinical trials including PREVENT, PRINCE, Val-MARC, LANCET, and the ongoing JUPITER trial evaluating the use of statin therapy among 18,000 apparently healthy individuals with low levels of LDL-C and elevated levels of CRP. Dr Ridker is also the Principal Investigator of the Women's Genome Health Study (WGHS), a comprehensive prospective genome wide association study being conducted among more than 25,000 initially healthy American women.
